Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ \[height (m)\]² * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45 Exclusion Criteria: * WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period * Any significant acute or chronic medical illness * Current or recent (within 3 months) gastrointestinal disease * Current smoker or recent (within 1 month) history of regular tobacco use * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population * Abnormal urinalysis at screening * Glucosuria at screening * Abnormal liver functions tests (ALT, AST or total bilirubin \> 10 % ULN) * Presence of edema on physical exam * History of diabetes mellitus * History of heart failure * History of renal insufficiency * History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months * Positive urine screen for drugs of abuse either at screening or before dosing * Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody * History of allergy to SGLT2 inhibitors, bumetanide (or related compounds) * History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) * Prior exposure to dapagliflozin within 3 months of Day -1 * Exposure to any investigational drug or placebo within 4 weeks of Day -1 * Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration * Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration * Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration